Abequolixron (RGX-104) and Durvalumab in Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations
- Status
- WITHDRAWN
- Phase
- PHASE1
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
- Status
- RECRUITING
- Phase
- PHASE2
Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
TRUDI: TDXD+Durva in HER2+/Low IBC
- Status
- RECRUITING
- Phase
- PHASE2
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab
- Status
- WITHDRAWN
- Phase
- PHASE2
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
- Status
- RECRUITING
- Phase
- PHASE1
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
- Status
- RECRUITING
- Phase
- PHASE2
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
- Status
- RECRUITING
- Phase
- PHASE2
Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE2
SIRT With Tremelimumab and Durvalumab for Resectable HCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3